← All candidates
105 insider filings on record.
105 filings on record.
RXRXRECURSION PHARMACEUTICALS, INC.
NasdaqGS · Healthcare · $1.71B
$3.19
-1.54% · Sep 16
105 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 22 sells
▸ hover a marker for the filing · drag to zoom · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.71B
Float
518.5M
97% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
31.2
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
100 more transactions on Pro →Context
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.22 act+$0.04
Q4 '25−$0.21 act+$0.11
Q3 '25−$0.36 act+$0.02
Q2 '25−$0.41 act−$0.06
Coverage
Recursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business UpdatesInsider Monkey · 06-05Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 ResultsSimply Wall St. · 06-04Recursion’s AI Drug Pipeline Progress Tests Investor Patience And ValuationSimply Wall St. · 06-04Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool · 06-02
The file stays open
105 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice